A reader arriving at any single article in this cluster is seeing one piece of a larger record. This page is the map.
The cluster covers one question: whether the mRNA vaccine platform carried residual plasmid DNA with an SV40 promoter-enhancer, at what quantities, by what documented mechanisms, and what the regulators' own records say about it. Each article stands on its own citations. The order below follows the story, not the publication dates.
Start anywhere. Article 2 is the flagship and the most complete single account. Grading standards and the correction policy are on the methodology page.
- 1 Origins Updated 5 October 2026A Foundational mRNA Assumption Under Challenge: What the 2026 Nature Biotechnology Paper Actually Shows
What the 2026 Nature Biotechnology mouse study actually shows: dendritic-cell expression is not required for mRNA-LNP immunity, and hepatocyte detargeting changes the platform picture.
- 2 The investigation Updated 5 October 2026SV40 DNA Contamination in COVID-19 mRNA Vaccines: The Definitive Investigation
The flagship record: eight independent laboratories, the SV40 promoter-enhancer in finished vials, the hybrid-protection mechanism, and the regulatory documents.
- 3 The mechanism Updated 5 October 2026mRNA Vaccine DNA Contamination: SV40 Promoter & Integration Risks
Forensic sequencing, the SV40 promoter's role in nuclear entry, and the regulators' own position papers on residual DNA.
- 4 The plasmid Updated 5 October 2026The BNT162b2 Plasmid Map: What EMA Confirmed and What the Public Sequence Shows
Eleven genetic elements of the BNT162b2 plasmid, confirmed in writing by the EMA, annotated from the public sequence.
- 5 The deposit Updated 5 October 2026The Host Genome They Said Was Not There: The Achs Sequencing Deposit Against the Achs Paper
Read-level reanalysis of the Achs et al. sequencing deposit: E. coli genomic DNA and circular plasmid where the paper reported none.
- 6 Manufacturing Updated 5 October 2026Pfizer Process 1 vs Process 2: Manufacturing Changes and Risks
The mid-trial manufacturing change from Process 1 to Process 2, and what it meant for residual DNA in the product.
- 7 Open questions Updated 5 October 2026Critical Research Gaps: What We Still Don't Know About DNA Contamination
The research agenda: persistence, dose response, integration assays, and what future studies must test.
- 8 The policy case Updated 5 October 2026Failed Resolution: An Evidence-Graded Case for Pausing the mRNA Platform
The evidence-graded case for pausing the mRNA platform, and what would have to change to lift it.
Adjacent work, different question
These articles start from the contamination record and ask what reduces the risk. They are defense and recovery material, not part of the investigation itself.